Anti-RNase L – Purified in vivo PLATINUM™ Functional Grade

Product No.: R6005

- -
- -
Clone
2e9
Target
RNaseL
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
2',5'-oligoisoadenylate synthetase-dependent; 2-5A-dependent ribonuclease; 2-5A-dependent RNase; interferon-induced 2-5A-dependent RNase; Ribonuclease 4; Ribonuclease L; ribonuclease L (2', 5'-oligoisoadenylate synthetase-dependent); ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent); RNase L; PRCA1; RNS4
Isotype
IgG1
Applications
ELISA
,
IHC FFPE
,
in vivo
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human/Hamster/Primate
Host Species
Mouse
Immunogen
Purified, full-length, recombinant, human RNaseL produced in insect cells.
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<0.5 EU/mg as determined by the LAL method
Purity
≥98% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Working Concentration
ELISA 1:100-1:2000
IHC-P 1:200-1:1000
WB 1:1000-1:4000
Applications and Recommended Usage?
Quality Tested by Leinco
WB
ELISA
Additional Applications Reported In Literature ?
IHC FFPE
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone 2E9 recognizes an epitope on human/hamster/primate RNaseL.
Background
RNase L antibody, clone 2E9, recognizes the interferon (IFN)-inducible 2-5A-dependent ribonuclease L (RNase L), an endoribonuclease involved in antiviral signaling. It is widely expressed as a latent monomer in most mammalian tissues1. 2’,5’-oligoadenylate synthetase (OAS) is expressed following viral infection and exposure to IFN2. OAS proteins are activated by dsRNA, resulting in the production of 2’,5’-linked oligoadenylates (2-5A), which bind to latent RNase L, inducing dimerization and activation2. RNase L inhibits viral replication by cleaving viral and ribosomal RNA3,4 and inducing apoptosis in virus-infected cells5,6. RNase L is suggested to have antitumor effects, possibly through its pro-apoptotic activity7, and mutations in the RNASEL gene are associated with prostate cancer risk and progression8,9.
Antigen Distribution
RNase L is highly expressed in the spleen and thymus, followed by prostate, testis, uterus, small intestine, colon, and peripheral blood leukocytes.

Antigen Details

PubMed
NCBI Gene Bank ID
Research Area
Cell Biology
.
Immunology
.
Neuroinflammation
.
Neuroscience

References & Citations

1. Zhou A, et al. (2005) J Interferon Cytokine Res. 25(10):595-603
2. Silverman RH. (2007) Cytokine Growth Factor Rev. 18(5-6):381-8
3. Wreschner DH, et al. (1981) Nucleic Acids Res. 9(7):1571-81
4. Cooper DA, et al. (2014) Nucleic Acids Res. 42(8):5202-16
5. Castelli JC, et al. (1997) J Exp Med. 186(6):967-72
6. Zhou A, et al (1997) EMBO J. 16(21):6355-63
7. Xiang Y, et al. (2003) Cancer Res. 63(20):6795-801
8. Meyer MS, et al. (2010) Carcinogenesis. 31(9):1597-603
9. Silverman RH. (2003) Biochemistry. 42(7):1805-12
Indirect Elisa Protocol
IHC FFPE
in vivo Protocol
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.